Citigroup Inc. grew its position in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 13.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 212,582 shares of the company’s stock after buying an additional 25,532 shares during the quarter. Citigroup Inc. owned 0.26% of Editas Medicine worth $1,658,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also modified their holdings of the company. State Street Corp grew its stake in Editas Medicine by 43.8% during the 2nd quarter. State Street Corp now owns 7,879,890 shares of the company’s stock worth $93,219,000 after purchasing an additional 2,399,852 shares in the last quarter. BlackRock Inc. grew its stake in Editas Medicine by 2.4% during the 2nd quarter. BlackRock Inc. now owns 7,595,696 shares of the company’s stock worth $62,513,000 after purchasing an additional 177,334 shares in the last quarter. Vanguard Group Inc. grew its stake in Editas Medicine by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 6,876,539 shares of the company’s stock worth $130,792,000 after purchasing an additional 202,642 shares in the last quarter. Marshall Wace LLP acquired a new position in Editas Medicine during the 2nd quarter worth $23,359,000. Finally, Woodline Partners LP grew its stake in Editas Medicine by 3.9% during the 2nd quarter. Woodline Partners LP now owns 2,749,305 shares of the company’s stock worth $22,627,000 after purchasing an additional 102,685 shares in the last quarter. 76.61% of the stock is owned by institutional investors and hedge funds.
Editas Medicine Stock Performance
Editas Medicine stock opened at $7.81 on Monday. Editas Medicine, Inc. has a fifty-two week low of $6.08 and a fifty-two week high of $11.91. The company has a market capitalization of $637.87 million, a P/E ratio of -2.89 and a beta of 1.96. The stock has a 50-day simple moving average of $8.68 and a 200-day simple moving average of $8.57.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the company. StockNews.com cut Editas Medicine from a “hold” rating to a “sell” rating in a research note on Thursday. Truist Financial boosted their target price on Editas Medicine from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $14.75.
Read Our Latest Report on EDIT
About Editas Medicine
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
See Also
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT – Free Report).
Receive News & Ratings for Editas Medicine Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Editas Medicine and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: americanbankingnews.com
